iBio (IBIO) vs Nomad Power Solutions (NMAD)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
iBio (IBIO) has outperformed Nomad Power Solutions (NMAD) over the past year, gaining 5.7% versus a loss of 11.2%. Over five years, NMAD leads with a -77.2% price change compared with -99.8% for IBIO. Nomad Power Solutions is the larger company by market cap ($68.8 million vs $59.2 million), about 1.2 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | IBIO | NMAD |
|---|---|---|
| Share price | $0.92 | $4.27 |
| Market cap | $59.16M | $68.75M |
| 1-day change | -8.91% | +0.47% |
| YTD return | -52.33% | +8.65% |
| 1-year return | +5.75% | -11.23% |
| 5-year return | -99.80% | -77.17% |
| EPS (TTM) | $-0.32 | $-1.01 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $3.82 | $8.38 |
| 52-week low | $0.78 | $2.36 |
| Distance from 52-week high | -75.92% | -49.05% |
| Analyst consensus | strong_buy | — |
| Avg. price target upside | +518.48% | — |
| Average volume | 735.37K | 277.61K |
| Shares outstanding | 64.31M | 16.10M |
| Employees | 23 | — |
| Sector | Healthcare | Industrials |
| Industry | Biotechnology | Electrical Equipment & Parts |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- IBIO has outperformed NMAD by 17.0 percentage points over the past year.
- The two companies sit in different sectors: iBio in Healthcare and Nomad Power Solutions in Industrials.
About iBio
IBIO stock →iBio, Inc., a preclinical stage biotechnology company, engages in the development of artificial intelligence (AI) antibodies solutions for cardiometabolic and obesity space. The company's technology platforms include EngageTx that provides a panel of optimized CD3 antibodies that can be paired with tumor-targeting antibodies to generate bispecific T-cell engagers; StableHu, an AI antibody-optimizing technology; and AI epitope steering technology, small binding sites on large target proteins Its product pipelines for cardiometabolic disease area include IBIO-601, a monoclonal antibody designed to block Activin E; IBIO-800, a bispecific antibody designed to inhibit myostatin and activin A signaling to preserve lean mass; IBIO-600 Myostatin Antibody, monoclonal antibody blocking myostatin that is in phase 1; Amylin Antibody, a pancreatic hormone that promotes satiety and appetite control through activation of the amylin receptor; CCR8, a Treg-targeting immunotherapy; and MUC16 antibodies.
Healthcare · Biotechnology · 23 employees
About Nomad Power Solutions
NMAD stock →NOMAD Power Solutions, Inc. develops utility-scale mobile energy storage systems on providing transportable solutions.
Industrials · Electrical Equipment & Parts
IBIO vs NMAD FAQ
Which is bigger, iBio or Nomad Power Solutions?
Nomad Power Solutions (NMAD) is larger, with a market capitalization of $68.75M compared with $59.16M for iBio (IBIO).
Which stock has performed better over the past year, IBIO or NMAD?
IBIO returned +5.75% over the past 12 months, compared with -11.23% for NMAD (price return, excluding dividends). Past performance does not predict future results.
Are iBio and Nomad Power Solutions in the same industry?
No. iBio is in the Healthcare sector, while Nomad Power Solutions is in Industrials.